Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by LithLoveron Apr 09, 2021 5:48pm
109 Views
Post# 32971324

RE:RE:Estimated revenue according to some sites for COC

RE:RE:Estimated revenue according to some sites for COCIf those numbers are true 15 million shares is a good deal.  Keep in mind an 8 million additional shares are available based on achieving certain performance milestones.

I'm just going off Lithlow but if they are doing $18 million and you add in Aristotle to get $20 million plus and the purchase price is 15 million shares.  Gotta think what that does for the share price and the message it sends to the market regarding the legitamacy and avaiablity of Aristotle.  

But I know lets lean in to the short attack.  I wonder why they want the shares.  Not much time to keep the short on now is it.

Short sighted paper hands lol.  Gotta have diamond hands and an eye on the long term.




LithLover wrote: So about $18 million Canadian.   And that's without our Aristotle test which is $1500 for 3000 patients with multiple testing.  

Hmmmmmm


Lithlow wrote: is 12 mil euro pr year. I do not know whether these sites are telling the truth, but I guess thats a good start..




<< Previous
Bullboard Posts
Next >>